Bremelanotide
Bremelanotide is a peptide, indexed here under Melanocortin receptor peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Melanocortin receptor peptides |
| CAS registry number | 189691-06-3[1] |
| PubChem CID | 9941379[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C50H68N14O10[1] |
| Molecular weight | 1025.2 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Bremelanotide is a melanocortin receptor agonist. A 2007 Journal of Sexual Medicine review covers preclinical central nervous system effects on female sexual function, and a 2006 paper in the same journal reports an effect on subjective sexual response in premenopausal women with sexual arousal disorder.
Clinical reporting in the retrieved set includes a 2016 randomised placebo-controlled trial in Womens Health and two randomised phase 3 trials reported in Obstetrics and Gynecology in 2019. A 2019 Drugs article records a first approval for the compound, and the FDA application register returned a current record.
[3, 4, 5, 6, 7]Reported mechanism
A melanocortin receptor agonist; the retrieved literature describes central nervous system mediated effects rather than peripheral ones.
[3]Stated in the title of the cited 2007 Journal of Sexual Medicine review of preclinical CNS effects.
Targets named in the cited records: melanocortin receptors.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA210557, marketed as VYLEESI (AUTOINJECTOR)). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Bremelanotide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- PT-141
- Vyleesi
Where this page sits
Research records
Cited research records for Bremelanotide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Bremelanotide
Compounds indexed next to it
- Melanotan II — Melanocortin receptor peptides
- Afamelanotide — Melanocortin receptor peptides
- Setmelanotide — Melanocortin receptor peptides
Named targets in the cited records
Class page: Melanocortin receptor peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Bremelanotide?
Bremelanotide is a melanocortin receptor agonist. A 2007 Journal of Sexual Medicine review covers preclinical central nervous system effects on female sexual function, and a 2006 paper in the same journal reports an effect on subjective sexual response in premenopausal women with sexual arousal disorder.
Which class is Bremelanotide indexed under?
Bremelanotide is indexed under Melanocortin receptor peptides. Melanocortin receptor peptides are analogues of alpha-melanocyte-stimulating hormone that act at melanocortin receptors.
What does the FDA application register show for Bremelanotide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA210557, marketed as VYLEESI (AUTOINJECTOR)). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 9941379, Bremelanotide. PubChem, National Library of Medicine (2026). pubchem:9941379
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA210557. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:bremelanotide
- Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med (2007). pmid:17958619
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med (2006). pmid:16839319
- Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) (2016). pmid:27181790
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol (2019). pmid:31599840
- Bremelanotide: First Approval. Drugs (2019). pmid:31429064
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.